drugset / Trial / NCT05867251
Study of AVZO-021 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Timeline
- Start
- 2023-08-30
- Primary completion
- 2028-01-31
- Completion
- 2030-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVZO-021 | Unknown | — | Oral |
| Subject | Abemaciclib | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Palbociclib | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | — |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | — |